Si-HPMC-encapsulated insulin-producing cells for the treatment of type 1 diabetes
The present invention relates to the use of insulin-producing cells encapsulated in silanized hydroxypropyl methylcellulose (Si-HPMC) for the treatment of type 1 diabetes. Methods and kits are also provided for restoring and/or maintaining euglycemia in type 1 diabetic patients and in type 1 prediabetic patients.
1. A method for treating type 1 diabetes in a patient, in particular for restoring and/or maintaining euglycemia in a type 1 diabetic patient or a type 1 prediabetic patient, said method comprising a step of administering to said patient a therapeutically effective amount of Si-HPMC-encapsulated insulin-producing cells, wherein the insulin-producing cells are macro-encapsulated in Si-HPMC flat-sheet membranes or in Si-HPMC hollow fiber membranes or wherein the insulin-producing cells are micro-encapsulated.
2. The method according to claim 1 , wherein Si-HPMC has the following simplified formula:
(HPMC)—O—CH 2 —CH(OH)—CH 2 —O—(CH 3 ) 3 —Si(O − Na + ) 3 (I).
3. The method according to claim 1 , wherein the insulin-producing cells are isolated allogenic pancreatic islets or isolated xenogenic pancreatic islets.
4. The method according to claim 1 , wherein the insulin-producing cells are isolated cells selected from the group consisting of pancreatic β-cells, pancreatic β-like cells, and any combination thereof.
5. The method according to claim 4 , wherein pancreatic β-like cells are obtained by differentiation of embryonic stem cells, induced pluripotent stem cells, multipotent mesenchymal stromal cells, ductal cells, hepatocytes, or β-cells.
6. The method according to claim 1 , wherein the insulin-producing cells are micro-encapsulated into Si-HPMC microbeads, Si-HPMC microspheres, or Si-HPMC microcapsules.
7. The method according to claim 1 , wherein the insulin-producing cells are encapsulated in Si-HPMC with at least one therapeutic compound.
8. The method according to claim 1 , wherein the type 1 diabetes patient suffers from brittle diabetes.
9. The method according to claim 1 , wherein the Si-HPMC-encapsulated insulin-producing cells are administered by subcutaneous injection, by intramuscular injection, or by implantation in the peritoneal cavity, in the mesentery, in the omemtum, or in the renal capsule.